Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Douglas Jay Cohen
AddedFeb 19, 2024
UpdatedMay 31, 2026
Douglas Jay Cohen

Douglas Jay Cohen

Board Member, VivoSim Labs

CrunchbaseLinkedInThe Org

Douglas Jay Cohen's Career

VivoSim Labs
VivoSim Labs

San Diego, CA, US

Board Member· Board
IR Medtek
IR Medtek

Gahanna, OH, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Douglas Jay Cohen's Career

VivoSim Labs
VivoSim Labs
Public$112.3M392011San Diego, CA, US
Board Member· Board

Leadership at VivoSim Labs

Adam K. SternAdam K. SternBoard Member
Taylor CrouchTaylor CrouchCEO
Gabor ForgacsGabor ForgacsFounder
Keith MurphyKeith MurphyBoard Member
Eric DavidEric DavidBoard Member

Similar to VivoSim Labs

3DBio3DBioNew York City, NY, USLiving Tissuesest. 20143DBioNew York City, NY, US · est. 2014

3DBio Therapeutics: Precision bioprinting for regenerative medicine, creating custom living tissues.

Public · $500k39
HistogenHistogenSan Diego, CA, USMedical Technologiesest. 2007HistogenSan Diego, CA, US · est. 2007

San Diego-based Histogen Inc. innovates patented medical technologies for aesthetic and therapeutic tissue replacement.

Public · $87.5M7
3D Biotek3D BiotekNorth Brunswick, NJ, USBioprinting, Cell Cultureest. 20073D BiotekNorth Brunswick, NJ, US · est. 2007

3D Biotek LLC: A biotech firm specializing in manufacturing 3D cell culture devices since 2007.

Angel · $225k4
Precise BioPrecise BioWinston-Salem, NC, USBio-Fabricated Organsest. 2015Precise BioWinston-Salem, NC, US · est. 2015

Precise Bio: Innovating in regenerative medicine through 4D bio-fabrication of tissues and organs.

Series A · $27.5M33
IR Medtek
IR Medtek
Seed$1.4M52019Gahanna, OH, US
Co-Founder

Leadership at IR Medtek

John ErbJohn ErbBoard Member
Andrew SpectorAndrew SpectorCo-Founder
Jonathan RamsdenJonathan RamsdenCo-Founder
John PascoeJohn PascoeCo-Founder

Douglas Jay Cohen's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Douglas Jay Cohen

Art LeibowitzArt LeibowitzBoard Member · Organogenesis HoldingsAdam AbateAdam AbateCo-Founder · Mission BioMark D. AngelinoMark D. AngelinoCo-Founder · Generation BioPiero MendezPiero MendezCo-Founder · Empire Biotechnologies